nicotine metabolism

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with smoking more cigarettes per day among HIV-positive smokers, replicating the well-established NMR-smoking rate relationship in the gen

Effect: decline; r = .30, p = .001 (univariate); b = 0.188, p = 0.050 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)

Higher nicotine metabolite ratio was significantly associated with higher anxiety symptoms among HIV-positive smokers in univariate analysis and marginally in the multivariate model.

Effect: decline; r = .26, p = .003 (univariate); b = 0.191, p = .054 (multivariate)